Losucon M 1 mg+500 mg (Tablet (Sustained Release))

Indications

• Adjunct to diet and exercise in type 2 diabetes mellitus patients
• Adequate glycemic control
• Combination therapy of glimepiride and metformin

Pharmacology

• Sulfonylurea antidiabetic agent
• Decreases blood glucose concentration
• Stimulates the release of insulin
• Improves insulin sensitivity
• Reduces basal hepatic glucose production
• Increases peripheral tissue sensitivity to insulin

Dosage

• Governing by desired blood glucose level
• Lowest dosage sufficient for metabolic control
• Regular blood and urine glucose level measurement
• Maximum recommended dose: 8 mg glimepiride, 2000 mg metformin

Administration

• Swallowed whole, not crushed or chewed

Interaction

• Metabolized by cytochrome P450 2C9 (CYP2C9)
• Potentiation of blood-glucose-lowering effect with concomitant drugs
• Weakening of blood-glucose-lowering effect with concomitant drugs
• Alcohol intake may potentiate or weaken action

Contraindications

• Hypersensitivity to glimepiride, metformin, sulfonylureas, sulfonamides
• Pregnant and breastfeeding women
• Severe impairment of liver function
• Severe renal failure or dysfunction

Side Effects

• Hypoglycemia
• Visual impairment
• Gastrointestinal symptoms
• Hepatitis and elevation of liver enzyme levels
• Alopecia
• Allergic or pseudo allergic reactions

Pregnancy & Lactation

• Glimepiride must not be taken during pregnancy
• Metformin should not be used during pregnancy
• Glimepiride must not be taken by breastfeeding women
• Metformin excreted into milk, decision should be made whether to discontinue nursing

Precautions & Warnings

• Increased risk of hypoglycemia in initial weeks of treatment
• Caution in patients with G6PD-deficiency
• Regular monitoring of thyroid-stimulating hormone levels

Use in Special Populations

• Insufficient data for pediatric use
• Assessment of GFR before initiation of treatment with metformin
• Renal function assessment in elderly and at increased risk

Overdose Effects

• Severe life-threatening hypoglycemia
• Lactic acidosis
• Pancreatitis may occur in the context of a metformin overdose

Therapeutic Class

• Combination Oral hypoglycemic preparations

Storage Conditions

• Cool and dry storage
• Protected from light

Related Brands